Lectures

Hepatitis: Diagnosis and Management

by John Fisher, MD
(1)

Questions about the lecture
My Notes
  • Required.
Save Cancel
    Learning Material 2
    • PDF
      Slides Hepatitis InfectiousDiseases.pdf
    • PDF
      Download Lecture Overview
    Report mistake

    About the Lecture

    The lecture Hepatitis: Diagnosis and Management by John Fisher, MD is from the course Gastrointestinal Infections.


    Included Quiz Questions

    1. Test for HCV RNA (viral load)
    2. Start interferon and lamivudine
    3. Start ribaviron
    4. Genetic testing
    5. Liver imaging studies
    1. Hepatitis B surface antigen and IgM mediated Hepatitis B core antibodies
    2. Hepatitis B surface antigen only
    3. Hepatitis B surface antigen, IgM mediated Hepatitis B core antibodies, IgM mediated Hepatitis A antibodies
    4. IgM mediated Hepatitis B core antibodies only
    5. Hepatitis B core antigens only
    1. Acute hepatitis A and acute hepatitis B infections
    2. Acute hepatitis A and chronic hepatitis B infections
    3. Chronic hepatitis B infection
    4. Chronic hepatitis A and B infections
    5. Acute hepatitis C infection
    1. No treatment; it is self limiting
    2. Ribavirin
    3. Counselling for chronic disease precautions
    4. Pegylated interferon
    5. Interferon-alpha and lamivudine combination treatment
    1. Chronic hepatitis B infection
    2. Acute hepatitis B infection
    3. Chronic hepatitis C infection
    4. Acute hepatitis C infection
    5. Acute hepatitis E infection

    Author of lecture Hepatitis: Diagnosis and Management

     John Fisher, MD

    John Fisher, MD


    Customer reviews

    (1)
    3,0 of 5 stars
    5 Stars
    0
    4 Stars
    0
    3 Stars
    1
    2 Stars
    0
    1  Star
    0
     
    Management section can be improved
    By Hamed S. on 27. March 2017 for Hepatitis: Diagnosis and Management

    Very comprehensive discussion. It would have been worthwhile to talk about criteria for starting treatment for chronic Hep B (e.g DNA count vs symptoms and livers functions). Also unclear if treatment of HepB is curative. The hepatitis talks did not mention genotypes of Hep C at all which is important for treating the condition, particularly in countries where access to direct acting antivirals is not available. Finally the talks didn't mention what percentage of patients with chronic Hep B and C go on to develop cirrhosis and hepatocellular carcinoma.